高级搜索
靳通通, 周川, 王超, 达子健, 周逢海. 前列腺癌免疫治疗研究热点的可视化分析[J]. 肿瘤防治研究, 2022, 49(7): 667-674. DOI: 10.3971/j.issn.1000-8578.2022.21.1486
引用本文: 靳通通, 周川, 王超, 达子健, 周逢海. 前列腺癌免疫治疗研究热点的可视化分析[J]. 肿瘤防治研究, 2022, 49(7): 667-674. DOI: 10.3971/j.issn.1000-8578.2022.21.1486
JIN Tongtong, ZHOU Chuan, WANG Chao, DA Zijian, ZHOU Fenghai. Research Hotspots and Frontiers of Immunotherapy for Prostate Cancer: A Visual Analysis[J]. Cancer Research on Prevention and Treatment, 2022, 49(7): 667-674. DOI: 10.3971/j.issn.1000-8578.2022.21.1486
Citation: JIN Tongtong, ZHOU Chuan, WANG Chao, DA Zijian, ZHOU Fenghai. Research Hotspots and Frontiers of Immunotherapy for Prostate Cancer: A Visual Analysis[J]. Cancer Research on Prevention and Treatment, 2022, 49(7): 667-674. DOI: 10.3971/j.issn.1000-8578.2022.21.1486

前列腺癌免疫治疗研究热点的可视化分析

Research Hotspots and Frontiers of Immunotherapy for Prostate Cancer: A Visual Analysis

  • 摘要:
    目的 通过对近20年发表的前列腺癌免疫治疗相关文献进行可视化分析,探讨前列腺癌免疫治疗领域研究进展及趋势。
    方法 检索Web of Science核心合集数据库2002至2021发布的前列腺癌免疫治疗相关文献。采用CiteSpace和VOSviewer进行数据可视化分析并绘制热点演进进程。
    结果 最终纳入2 326篇文献。研究表明前列腺癌免疫治疗领域处于快速发展阶段,美国在该领域内影响力巨大,中国后发优势明显;美国国家癌症研究所、纪念斯隆-凯特琳癌症中心和加利福尼亚大学旧金山分校是该领域主要研究机构;美国作者Gulley JL、Schlom J和日本作者Itoh K在该领域内发文量最多。当前,前列腺癌免疫治疗的主要研究热点是免疫检查点抑制剂,而高质量的临床试验在不断推动其发展。
    结论 新型免疫途径的探索及不同疗法间的联合将成为该领域未来研究的主要趋势。

     

    Abstract:
    Objective To visualize and analyze the literature related to immunotherapy for prostate cancer published in the past 20 years through bibliometric analysis, and to explore the research progress and cutting-edge trends in this field.
    Methods The Web of Science core collection database was searched for literature related to immunotherapy for prostate cancer published from 2002 to 2021. CiteSpace and VOSviewer software were used to visualize and analyze the data and map the evolution of hotspots.
    Results There were 2 326 papers were finally included after excluding irrelevant studies. The field of immunotherapy for prostate cancer is in a rapid development stage; the United States has a great influence and China has a significant latecomer advantage; the National Cancer Institute, Memorial Sloan-Kettering Cancer Center and University of California, San Francisco are the main research institutions; American authors Gulley JL, Schlom J and Japanese author Itoh K have the highest number of publications. Currently, the main research hotspot is immune checkpoint inhibitors, and high-quality clinical trials are continuing to drive this process forward.
    Conclusion The exploration of novel immune pathways and the combination of different therapies will be the main trend of future research in immunotherapy for prostate cancer.

     

/

返回文章
返回